⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SABS News
SAB Biotherapeutics, Inc. Common Stock
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
SABS
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
SABS
SABSW
Form 8-K
sec.gov
SABSW
SABS
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
globenewswire.com
SABS
SABSW
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
globenewswire.com
SABS
SAB BIO to Participate in Upcoming Investor Conferences
globenewswire.com
SABS
SABSW
SAB BIO to Participate in Upcoming Investor Conferences
globenewswire.com
SABS
SABSW
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
globenewswire.com
SABS
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
SABS
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
globenewswire.com
SABS